Clinical trials: Depression Symptom
Depression, Depressive Disorder
Assessment of the Safety and Effectiveness of Cortical Stimulation in Subjects With Major Depressive Disorder
The purpose of this study is to assess the safety and effectiveness of cortical stimulation to the cerebral cortex of subjects who have suffered from treatment-resistant depression and have failed routine attempts at controlling…
- Trial name
- PROSPECT (NCT00380042)
- Testing
- Cortical Stimulation
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Northstar Neuroscience
Pregnancy, Migraine
External Trigeminal Nerve Stimulation for Migraine Treatment in Pregnancy
This online registry aims to understand the potential benefits and safety of external trigeminal nerve stimulation for the treatment of migraine in pregnant women.
- Conditions
- Pregnancy, Migraine, Headache, Postpartum
- Trial name
- NCT06788977
- Testing
- external Trigeminal Nerve Stimulation
- Where
- United States
- Volunteers
- 550 people
- Sponsor
- Cefaly Technology
Depression
To Demonstrate the Relative Bioavailability of Bupropion HCI 300 mg Extended-Release Tablets Under Fasting Conditions
The purpose of this study is to demonstrate the relative bioequivalence of Bupropion HCI 300 mg ER Tablets under fasting conditions.
- Trial name
- NCT00861939
- Testing
- Bupropion HCI 300 mg Extended-Release Tablets EON, WELLBUTRIN XL 300 mg Extended-Release Tablets GlaxoSmithKline
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Sandoz
Anhedonia, Major Depressive Disorder (MDD)
Efficacy of kTMP, a Novel Non-invasive Brain Stimulation Method, for the Treatment of Anhedonia
The goal of this proposal is to provide a first assessment of the efficacy of our innovative non-invasive brain stimulation system, kTMP, in the treatment of anhedonia in MDD.
- Trial name
- kTMP Anhedonia (NCT07032428)
- Testing
- A new non-invasive brain stimulation tool
- Volunteers
- 104 people
- Sponsor
- Magnetic Tides
Major Depressive Disorder, Recurrent, Unspecified
Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005
Objectives To evaluate the safety and tolerability of escalating multiple oral doses of LY03005 in healthy subjects. To characterize the pharmacokinetics of escalating multiple oral doses of LY03005.
- Trial name
- NCT02271412
- Testing
- LY03005
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Depressive Disorder, Major
A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00208156
- Testing
- Mifepristone
- Where
- 13 sites in United States
- Volunteers
- 87 people
- Sponsor
- Corcept Therapeutics
Multiple Myeloma
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
1. Planned enrollment period One year (The planned number of patients to be enrolled is set to 400 patients.) Since all patients who are prescribed with Pomalyst are registered in RevMate®, enrollment using the Registration Form…
- Trial name
- NCT02921828
- Where
- 2 sites in United States, Japan
- Volunteers
- 1,149 people
- Sponsor
- Celgene
Depression
To Demonstrate the Relative Bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Healthy Adult Males Under Fasting Conditions
To demonstrate the relative bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride capsules (Pulvules) in healthy adult males under fasting conditions.
- Trial name
- NCT00913718
- Testing
- Fluoxetine Hydrochloride 20 mg Capsules (Geneva Pharmaceutical, Inc.), Prozac Fluoxetine Hydrochloride 20 mg Capsules (Dista)
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Sandoz
Major Depressive Disorder, MDD
A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken for 52 weeks with another antidepressant…
- Conditions
- Major Depressive Disorder, MDD, Depression
- Trial name
- NCT01152554
- Testing
- TC-5214
- Where
- 94 sites in United States, Puerto Rico
- Volunteers
- 813 people
- Sponsor
- AstraZeneca
Anxiety, Depression, Anxiety
Study to Identify if OVR Health's VR-Kit is Safe to Use and Helps to Improve Focus, Attention and Reduce Worry & Rumination.
This is a randomized-controlled interventional treatment study with three arms of comparable demographics to evaluate the safety and efficacy of OVR Health's VR experience to improve control over the focus of attention and reduce…
- Trial name
- NCT05291429
- Testing
- OVR Health's VR experience
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Oxford VR
Mild Cognitive Impairment, Alzheimer's Disease
Effect of Cerefolin®/CerefolinNAC® on Biomarker Measurements
In a retrospective analysis of data from 1100 patients, disease-delaying effects of Cerefolin®/CerefolinNAC® were examined in terms of cognition.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease Related Disorders
- Trial name
- NCT01745198
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Pamlab, Inc.
Job Satisfaction, Work Performance
Life Skills Training Workplace Prevention Program
A workplace health promotion intervention for youth age 16-24
- Conditions
- Job Satisfaction, Work Performance, Health Care Utilization, Depression Symptoms
- Trial name
- LST-WP (NCT06745739)
- Testing
- Life Skills Training Workplace Prevention Program
- Volunteers
- 1,145 people, healthy volunteers welcome
- Sponsor
- National Health Promotion Associates, Inc.
Major Depressive Disorder
AZD7268 Safety and Tolerability Study
The purpose of this study is to prove the principle that treatment with AZD7268 reduces depressive symptoms in patients with Major Depressive Disorder (MDD) compared with placebo.
- Trial name
- NCT01020799
- Testing
- AZD7268, Escitalopram
- Where
- 17 sites in United States
- Volunteers
- 247 people
- Sponsor
- AstraZeneca
Sleep Initiation and Maintenance Disorders, Depression
STILDEP: Zolpidem in Depressive and Dysthimic Patients
Primary objective: To show that the combination of Zolpidem + antidepressant therapy is more effective in the treatment of the secondary insomnia of depressive and dysthimic patients than antidepressant therapy alone in the acute…
- Trial name
- NCT00292734
- Testing
- Zolpidem
- Where
- Hungary
- Volunteers
- 120 people
- Sponsor
- Sanofi
Major Depressive Disorder
Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder
This study will assess efficacy, safety and tolerability of agomelatine (AGO178) 25 mg and 50 mg in patients with Major Depressive Disorder (MDD). This study includes an 8-week double-blind phase and a 52-week open-label phase.
- Trial name
- NCT00411099
- Testing
- agomelatine
- Where
- 44 sites in United States, Puerto Rico
- Volunteers
- 508 people
- Sponsor
- Novartis
Depression
To Demonstrate the Relative Bioequivalency of Comparing Single 100 mg Doses Of Cord's 50 mg Desipramine HCL Tablets To Merrell Dow's 50 mg Norpramin Tablets
To demonstrate the relative bioequivalency of comparing single 100 mg doses Of Cord's 50 mg Desipramine Hcl tablets to Merrell Dow's 50 mg Norpramin tablets.
- Trial name
- NCT00914004
- Testing
- Desipramine HCl 50 mg Tablets Cord Laboratories, Norpramin 50 mg Tablets Merrell Dow Pharmaceuticals, Inc
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sandoz
Major Depressive Disorder
Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder
This study will evaluate the long-term safety and tolerability of escitalopram (Lexapro) in children 7 to 11 years of age with major depressive disorder (MDD).
- Trial name
- NCT01198795
- Testing
- Escitalopram
- Where
- 16 sites in United States
- Volunteers
- 162 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
This is a Double-blind Study Evaluating Desvenlafaxine Succinate (DVS SR) Sustained Release vs Placebo in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (MDD).
- Trial name
- NCT01372150
- Testing
- desvenlafaxine succinate sustained release, fluoxetine
- Where
- 43 sites in United States, Mexico
- Volunteers
- 340 people
- Sponsor
- Pfizer
Depressive Disorder, Major, Suicidal Ideation
A Study to Describe Routine Treatment Pathways in Participants With Major Depression and Active Suicidal Ideation With Intent in Italy
The purpose of the study is to describe the pharmacological and non-pharmacological treatment utilization pathways in Italian routine clinical practice of participants with Major Depressive Disorder (MDD) and active suicidal…
- Trial name
- ARIANNA (NCT04463108)
- Testing
- No Intervention
- Where
- 24 sites in Italy
- Volunteers
- 136 people
- Sponsor
- Janssen-Cilag S.p.A.
Major Depressive Disorder
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
The primary objective of this study is to assess whether LY2216684 12 milligrams (mg) or 18 mg flexible dose once daily is superior to placebo once daily in the adjunctive treatment of participants with major depressive disorder…
- Trial name
- NCT01185340
- Testing
- LY2216684, SSRI
- Where
- 49 sites in United States, Australia and 5 more
- Volunteers
- 1,056 people
- Sponsor
- Eli Lilly and Company